SHANGHAI, China, June 12, 2026 — DualityBiologics (DualityBio, HKEX: 9606.HK, or the "Company") today announced that the Shanghai Stock Exchange (SSE) has officially accepted the Company’s application for its initial public offering of RMB ordinary shares (A Shares) and listing on the Science and Technology Innovation Board (the "STAR Market"). The prospectus (application proof) for the STAR Market listing (A-Share Prospectus) has been pre-disclosed on the SSE STAR Market Issuance and Listing Review website (https://www.sse.com.cn/listing/renewal/ipo/). This milestone marks the official launch of DualityBio’s journey toward an "H+A" dual-capital market layout following its successful listing on the Hong Kong Stock Exchange.

The proceeds from this public offering will be allocated to the Company’s novel drug research and development projects. By continuously intensifying efforts to overcome core independent technical bottlenecks, the Company aims to further accelerate the R&D and commercialization of innovative drugs, deliver best-in-class therapies to patients, and reward shareholders and investors with high-quality corporate growth.

Mr. Shaoren Zhang, Chief Financial Officer of DualityBio, commented:"The smooth acceptance of our STAR Market IPO application is a vital step for DualityBio to root itself in China's fertile ground for innovation and leverage the domestic capital market for growth. Supported by national policies favoring 'hard tech' and innovative drugs, alongside the dividends from the continuous, deepening reforms of the STAR Market, DualityBio has stood out through our leading ADC technology and global pipeline. This represents high recognition of our innovation capabilities from both the industry and the market.Deploying an 'H+A' dual-platform is a long-term strategic choice for the Company. It not only demonstrates our full confidence in the Chinese capital market but will also further expand our domestic investor base. Moving forward, DualityBio will seize this opportunity to accelerate the global clinical and commercial pace of our core ADC products, striving to set a benchmark for Red-Chip innovative drug companies returning to the A-share market, while benefiting global patients with our innovative achievements."

About DualityBio

DualityBio is a clinical-stage innovative biopharmaceutical company focusing on the development of next-generation antibody-drug conjugates (ADCs) for patients with cancer and autoimmune diseases. The Company has successfully built multiple next-generation ADC technology platforms with global intellectual property rights. Based on deep insights and exploration of disease biology mechanisms, DualityBio boasts a rich clinical ADC R&D pipeline and is conducting multiple global multi-center clinical trials in nearly 20 countries, with over 3,500 patients enrolled. Meanwhile, DualityBio has reached multiple out-licensing collaborations with global pharmaceutical giants and top innovative biotech companies. As a global engine for ADC innovation, DualityBio continues to develop next-generation novel ADCs, including bispecific ADCs, ADCs with payloads of novel mechanisms, and autoimmune ADCs.

• For more information, please visit: www.dualitybiologics.com

• Media Contact: PR@dualitybiologics.com

• Investor Contact: IR@dualitybiologics.com

Disclaimer

Shareholders and potential investors of the Company should note that the proposed RMB Share Issuance is subject to necessary regulatory approvals and there is no assurance that the RMB Share Issuance will materialize or when it will materialize. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. The Company will make further announcements on any material updates and progress regarding the RMB Share Issuance at the appropriate time in accordance with the Hong Kong Listing Rules and other applicable laws and regulations. This announcement is for information purposes only and does not, and is not intended to, constitute an invitation or offer to acquire, purchase, or subscribe for any shares of the Company.